At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
In Brief
A Phase 4 clinical trial evaluating Galcanezumab and Erenumab for Migraine. Completed, enrolled 65 participants across 3 sites.
Detailed Summary
The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezumab or erenumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedMar 2020
Enrollment StartOct 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedMar 3, 2020
Enrollment StartOct 6, 2020
Primary CompletionMar 5, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.3 years ago
Interventions
Galcanezumabdrug
Administered SC
Erenumabdrug
Administered SC